Jinling Pharmaceutical announced that the drug registration and marketing authorization application for Carboxymaltose Iron Injection from its branch, Fuzhou Meifeng Pharmaceutical Factory, has been accepted by the National Medical Products Administration. This drug is a third-generation intravenous iron agent used for treating iron deficiency anemia. Currently, only the original imported product is available on the domestic market. If approved, it will enrich the company's product pipeline and strengthen its competitive advantage in the iron supplement field.
Jinling Pharmaceutical Co LtdMarketing authorization application accepted for new drug, expanding pipeline and competitive edge.